BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

JW Pharmaceutical’s Epaminurad Shows Statistical Superiority in Phase III Gout Trial

-JW Pharmaceutical (KRX:001060) announced that the multinational Phase 3 clinical trial of its gout treatment candidate ‘Epaminurad (code name U...

August 17, 2026 | News

Optellum, Coreline Soft Join Forces to Build Integrated AI Pathway for Lung Nodule Care

Proposed collaboration would make Coreline Soft's FDA-cleared lung nodule detection capability available through Optellum's LungOS® platform &nbs...

August 17, 2026 | News

SK bioscience Seeks South Africa Approval to Begin Phase 1b Trial of RSV Preventive Antibody RSM01

Phase 1b study will evaluate safety and pharmacokinetics of RSM01 in approximately 80 infants aged 2 weeks to 8 months Company expands its global portfo...

August 17, 2026 | News

Alteogen Signs Up to $365 Million Hybrozyme Licensing Deal for Subcutaneous Biologic

Alteogen grants exclusive rights to develop and commercialize a subcutaneous biologic product using Hybrozyme™-based hyaluronidase ALT-B4 Alteogen...

August 07, 2026 | News

Adneuris Licenses Cebranopadol Rights to Maruishi for Japan and South Korea

Agreement Grants Maruishi Rights for the Development and Commercialization of Cebranopadol for Pain in Japan and South Korea, Marking Adneuris' Second Ex...

August 07, 2026 | News

Vaxcellbio Partners with Myellama to Advance Next-Generation NK Cell Therapy for Multiple Myeloma

Vaxcellbio (CEO Je-Jung Lee, MD, PhD), a leading immuno-oncology company, announced today that it has signed a strategic Memorandum of Understanding ...

August 05, 2026 | News

Seegene Advances Comprehensive HPV and STI PCR Testing with Large-Scale Clinical Evidence

STAgora™ analysis of approximately 60,000 test results collected over 42 months showed that STI pathogens were detected in 82% of HPV-positive case...

July 29, 2026 | News

7 Countries Competing to Be the Region’s Next Biomanufacturing Hub

A siting decision for a biomanufacturing facility is one of the most expensive commitments a company makes, and it is made against a fifteen to twenty year...

July 27, 2026 | Analysis

Samsung Bioepis Secures Exclusive Commercial Rights to Nectin-4 ADC Candidate SBE303

Ÿ Under the agreement, Samsung Bioepis will obtain exclusive commercial licensing rights to SBE303, an ADC candidate currently in joi...

July 24, 2026 | News

Menarini Asia-Pacific, Pharmacosmos Partner to Expand Cosela® Access Across APAC

Menarini Asia-Pacific announced an exclusive partnership with Pharmacosmos A/S to register, commercialise and distribute Cosela® (trilaciclib) acr...

July 23, 2026 | News

Samsung Biologics Launches CHF 1.46B All-Cash Bid to Acquire PolyPeptide

Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding therefrom any treasury share...

July 21, 2026 | News

Why Korea, Why Now? Korean Biotech Looks to Taiwan as Asia’s Next Partnership Frontier

Korea’s biotechnology industry is entering a new phase of global ambition. Having established significant capabilities across biopharmaceutical manuf...

July 20, 2026 | News

APAC's Peptide-Capacity Gamble

For most of pharmaceutical history, the hard part was finding a molecule that worked. The GLP-1 class inverted that logic. The science arrived first &mdash...

July 09, 2026 | Analysis

LG Chem and OTR Therapeutics Partner to Advance China-Sourced Oncology Assets Globally

OTR Therapeutics, a clinical-stage biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies, today an...

July 09, 2026 | News

Stay Connected